NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation DXR, an innovative medical instrumentation and biotechnology company focused on blood volume measurement, announced that Michael Feldschuh, chief executive officer of Daxor, will be a featured presenter at the LD Micro Invitational Conference on Monday June 4, 2018 at 4:30 PM Pacific Time. The conference is being held at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.
Mr. Feldschuh will provide an overview of the company's business model and growth strategy, and will be available for one-on-one meetings. Interested investors may request a meeting time by contacting Bret Shapiro, at COREIR, either by calling 516-222-2560 or via brets@coreir.com.
About Daxor
Daxor Corporation is an innovative medical instrumentation and biotechnology company. We manufacture the BVA-100 Blood Volume Analyzer, the first instrument cleared by the FDA to provide rapid direct measurement of a patient's blood volume and optimal volume. Since its introduction the BVA-100 Blood Volume Analyzer has been used in over 40,000 clinical cases and numerous research studies highlighting its potential to transform therapy in a broad range of surgical and medical conditions The company's mission is to help hospitals and physicians incorporate DAXOR's advanced technologies to significantly improve the quality of patient care. For more information please visit our website at http://www.daxor.com/.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Information: Daxor Corporation Soren Thompson Investor Relations 212-330-8502 sthompson@daxor.com Investor Relations Contact: Bret Shapiro Sr. Managing Director CORE IR 561-479-8566 brets@coreir.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
